Brasil Maria Vitoria Oliveira Moura, Rockwood Edward J, Smith Scott D
Cole Eye Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
J Glaucoma. 2007 Jan;16(1):36-41. doi: 10.1097/01.ijg.0000243477.82779.31.
To compare the efficacy and safety of silicone and polypropylene Ahmed Glaucoma Valves (AGVs) in patients with refractory glaucoma.
A retrospective chart review of 180 eyes of 166 patients who underwent AGV implantation with a minimum follow-up period of 3 months was performed. All patients who underwent implantation of either the AGV model S-2 (polypropylene) or model FP-7 (silicone) were included, unless previous laser cyclophotocoagulation had been performed. The primary outcome measures were the change in intraocular pressure (IOP) and visual acuity after surgery and the rate of postoperative complications.
No significant differences were seen in the baseline characteristics of patients in each group. Baseline IOP was statistically equivalent in the 2 groups (silicone =33.8+/-11.9 mm Hg, polypropylene=33.0+/-10.3 mm Hg, P=0.6). A significant reduction in IOP from baseline was achieved after both silicone and polypropylene AGV implantation (silicone =-17.7+/-11.8 mm Hg, polypropylene =-17.7+/-11.3 mm Hg, both P<0.00005). However, there was no statistically significant difference in IOP decrease between the 2 groups at any follow-up visit (all P>0.09). The mean number of postoperative antiglaucoma medications was also similar in the silicone and the polypropylene AGV groups at each time point (all P>0.2). The rate of complications and the change in visual acuity did not differ between the 2 groups (P>0.6 and P>0.3, respectively).
Silicone and polypropylene AGVs have similar results with respect to both safety and efficacy in the treatment of patients with refractory glaucoma.
比较硅酮和聚丙烯阿赫迈德青光眼引流阀(AGV)在难治性青光眼患者中的疗效和安全性。
对166例患者的180只眼进行AGV植入术,进行回顾性病历审查,随访期至少3个月。所有接受S-2型(聚丙烯)或FP-7型(硅酮)AGV植入的患者均纳入研究,除非之前已进行过激光睫状体光凝术。主要观察指标为术后眼压(IOP)和视力变化以及术后并发症发生率。
每组患者的基线特征无显著差异。两组的基线眼压在统计学上相当(硅酮组=33.8±11.9 mmHg,聚丙烯组=33.0±10.3 mmHg,P=0.6)。硅酮和聚丙烯AGV植入术后眼压均较基线显著降低(硅酮组=-17.7±11.8 mmHg,聚丙烯组=-17.7±11.3 mmHg,P均<0.00005)。然而,在任何随访时两组间眼压降低幅度均无统计学显著差异(所有P>0.09)。在每个时间点,硅酮和聚丙烯AGV组术后抗青光眼药物的平均使用数量也相似(所有P>0.2)。两组间并发症发生率和视力变化无差异(分别为P>0.6和P>0.3)。
在治疗难治性青光眼患者时,硅酮和聚丙烯AGV在安全性和疗效方面结果相似。